KR20220044496A - 전립선 특이적 막 항원(psma) 리간드 및 이의 용도 - Google Patents

전립선 특이적 막 항원(psma) 리간드 및 이의 용도 Download PDF

Info

Publication number
KR20220044496A
KR20220044496A KR1020227003148A KR20227003148A KR20220044496A KR 20220044496 A KR20220044496 A KR 20220044496A KR 1020227003148 A KR1020227003148 A KR 1020227003148A KR 20227003148 A KR20227003148 A KR 20227003148A KR 20220044496 A KR20220044496 A KR 20220044496A
Authority
KR
South Korea
Prior art keywords
formula
compound
psma
cancer
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227003148A
Other languages
English (en)
Korean (ko)
Inventor
마우리치오 에프. 마리아니
로렌차 푸가차
다니엘라 키코
마틴 길버트 폼퍼
산게타 레이
Original Assignee
어드밴스드 액셀러레이터 어플리케이션즈 (이태리) 에스알엘
더 존스 홉킨스 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 어드밴스드 액셀러레이터 어플리케이션즈 (이태리) 에스알엘, 더 존스 홉킨스 유니버시티 filed Critical 어드밴스드 액셀러레이터 어플리케이션즈 (이태리) 에스알엘
Publication of KR20220044496A publication Critical patent/KR20220044496A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/38—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020227003148A 2019-07-02 2020-06-30 전립선 특이적 막 항원(psma) 리간드 및 이의 용도 Pending KR20220044496A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19184015.6 2019-07-02
EP19184015 2019-07-02
PCT/EP2020/068386 WO2021001360A1 (en) 2019-07-02 2020-06-30 Prostate specific membrane antigen (psma) ligands and uses thereof

Publications (1)

Publication Number Publication Date
KR20220044496A true KR20220044496A (ko) 2022-04-08

Family

ID=67145647

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227003148A Pending KR20220044496A (ko) 2019-07-02 2020-06-30 전립선 특이적 막 항원(psma) 리간드 및 이의 용도

Country Status (16)

Country Link
US (1) US20230226227A1 (https=)
EP (1) EP3993837A1 (https=)
JP (2) JP7805170B2 (https=)
KR (1) KR20220044496A (https=)
CN (3) CN120441497A (https=)
AR (1) AR119331A1 (https=)
AU (3) AU2020299974A1 (https=)
BR (1) BR112021026812A2 (https=)
CA (1) CA3144557A1 (https=)
CL (1) CL2021003525A1 (https=)
CO (1) CO2021017708A2 (https=)
IL (1) IL289039B1 (https=)
MX (1) MX2022000136A (https=)
PH (1) PH12021553284A1 (https=)
TW (1) TW202114742A (https=)
WO (1) WO2021001360A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230330278A1 (en) * 2020-04-29 2023-10-19 Novartis Ag Methods for radiolabelling psma binding ligands and their kits
KR20260040237A (ko) 2023-07-21 2026-03-24 노파르티스 아게 Psma 표적 방사성 리간드 치료 요법
WO2025125469A1 (en) 2023-12-13 2025-06-19 Swiss Rockets Ag Combination therapy using psma-targeted radiopharmaceuticals and an inhibitor of pi3k, akt, and/or mtor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001271026A1 (en) 2000-07-11 2002-01-21 Bml, Inc. Remedies for bone diseases
WO2013022797A1 (en) * 2011-08-05 2013-02-14 Molecular Insight Pharmaceuticals Radiolabeled prostate specific membrane antigen inhibitors
LT4095130T (lt) * 2013-10-18 2024-04-25 Novartis Ag Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti
HRP20240215T1 (hr) * 2016-03-22 2024-04-26 The Johns Hopkins University Sredstva sa visokim afinitetom za ciljani učinak na membranski antigen specifičan za prostatu za endoradioterapiju raka prostate
WO2018222778A1 (en) * 2017-05-30 2018-12-06 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
KR20250126870A (ko) * 2018-02-06 2025-08-25 더 존스 홉킨스 유니버시티 암 방사선 치료를 위한 psma 표적 방사성 할로겐화 우레아-폴리아미노카복실레이트
WO2020028323A1 (en) * 2018-07-30 2020-02-06 The Johns Hopkins Universtiy Competitive prostate-specific membrane antigen (psma) binding agents for the reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy

Also Published As

Publication number Publication date
US20230226227A1 (en) 2023-07-20
AU2024200850B2 (en) 2025-09-04
CN120441497A (zh) 2025-08-08
TW202114742A (zh) 2021-04-16
JP7805170B2 (ja) 2026-01-23
PH12021553284A1 (en) 2022-08-01
AU2024200850A1 (en) 2024-02-29
JP2022538478A (ja) 2022-09-02
BR112021026812A2 (pt) 2022-02-22
JP2025165975A (ja) 2025-11-05
CN120441498A (zh) 2025-08-08
IL289039B1 (en) 2026-03-01
AU2025271182A1 (en) 2025-12-18
IL289039A (en) 2022-02-01
CL2021003525A1 (es) 2022-10-21
CA3144557A1 (en) 2021-01-07
CN114341118A (zh) 2022-04-12
MX2022000136A (es) 2022-04-27
EP3993837A1 (en) 2022-05-11
AU2020299974A1 (en) 2022-01-27
AR119331A1 (es) 2021-12-09
CO2021017708A2 (es) 2022-05-20
WO2021001360A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
JP7036774B2 (ja) 前立腺特異的膜抗原（ｐｓｍａ）の標識インヒビター、前立腺癌の治療のための画像化剤および薬剤としてのその使用
JP7059372B2 (ja) デュアルモードの放射性トレーサーおよび療法剤
Muller Folate based radiopharmaceuticals for imaging and therapy of cancer and inflammation
KR20250171419A (ko) 납 또는 토륨 방사성핵종에 연결된 psma-타게팅 화합물을 포함하는 복합체
Lane et al. Optimization, biological evaluation and microPET imaging of copper-64-labeled bombesin agonists,[64Cu-NO2A-(X)-BBN (7–14) NH2], in a prostate tumor xenografted mouse model
ligan et al. 99mTc-ethylenedicysteine-folate: a new tumor imaging agent. Synthesis, labeling and evaluation in animals
WO2020065045A1 (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
JP2025165975A (ja) 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用
CN106660943A (zh) 用于psma靶向的成像和放射疗法的金属/放射性金属标记的psma抑制物
EP3209336A1 (en) 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
JP2022513630A (ja) 治療および画像化のためのデンドリマー
KR20260040237A (ko) Psma 표적 방사성 리간드 치료 요법
Wang et al. Synthesis, radiolabeling and biodistribution studies of [99m Tc (CO) 3 (MN-TZ-BPA)]+ in tumor-bearing mice
JP7788524B2 (ja) 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用
Huang et al. Advancing cancer therapy with a heptamethine carbocyanine dye-conjugated radionuclide drug
CN119874628B (zh) 一种含氮化合物及其制备方法与用途
Wang et al. Synthesis and biological evaluation of 99mTc (CO) 3 (His–CB) as a tumor imaging agent
JPH03261786A (ja) ポルフィリン金属複合体とその用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000